893 results on '"Efebera, Yvonne"'
Search Results
2. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)
3. Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
4. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
5. Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy
6. Unusual location and presentation of wild type Transthyretin Amyloidosis: A case series
7. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
8. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
9. Prospective two center study of CD38 bright CD8+ effector memory T-cells as a predictor of acute GVHD
10. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
11. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
12. Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
13. Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial
14. Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
15. Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells
16. Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up
17. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma
18. Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy
19. Data from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
20. Lenalidomide in the treatment of anti‐myelin‐associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose
21. Improvement in survival of acute myeloid leukemia and myelodysplastic syndrome patients following allogeneic transplant: a long-term institutional experience
22. A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial
23. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
24. Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation
25. BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin’s lymphomas
26. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma
27. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant
28. Lenalidomide in the treatment of anti‐myelin‐associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.
29. Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial
30. P-020 Dendritic cell/myeloma fusion vaccine with lenalidomide maintenance following autologous hematopoietic cell transplant (HCT) results in long-term sustained T cell activation and clonotypic expansion
31. P-302 Anchor (OP-104): melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/ refractory multiple myeloma (RRMM) – final efficacy and safety results
32. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma—final results of a phase I/IIa study
33. Study Representativeness Table 1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
34. Figure S1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
35. P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS
36. Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
37. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
38. Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?
39. Ninety-minute daratumumab infusion is safe in multiple myeloma
40. The first relapse in multiple myeloma: how to pick the next best thing
41. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma
42. Abstract 6785: Dendritic cell/myeloma fusion vaccine with lenalidomide maintenance following autologous hematopoietic cell transplant induced T cell activation and expansion
43. Abstract 17058: Phenotypically Sex Differences in Transthyretin Amyloidosis V122I Mutation Patients
44. Abstract 16887: Utilization of Cardiovascular Procedures in Cardiac Amyloidosis
45. Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease
46. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
47. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
48. Supplementary table 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
49. Supplementary table 2 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
50. supplemental legend from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.